CFDA just released on April 25, 2018, its Public Comment Draft of Pharmaceutical Data Exclusivity Implementing Rules (provisional) 药品试验数据保护实施办法（暂行）征求意见稿, available here (the web version is here). Comments are due by May 31, 2018, at firstname.lastname@example.org.
Article 5 proposes six-year data protection (which was China’s WTO commitment) for “innovative new drugs”. “Innovative therapeutic biologics” are eligible for 12-year data protection (the previous May 2017 CFDA circular said 10 years). The draft clearly encourages MNCs to include China in international multicenter clinical trials and to concurrently apply for market introduction in China (which can include other countries). Full-term protection (6/12 years) is only available in this scenario. Reduced Chinese data protection terms of one to five years may occur due to delays in introduction in China. As a policy matter, this draft appears intended to help encourage conducting clinical trials in China as well as new product introduction into the Chinese market
Thanks to my friend and former student Jill (Yijun) Ge at Clifford Chance for bringing this to my attention and providing an initial review. I welcome readers to submit English translations of this draft for me to post.
This is one of several exciting new developments in the pharma IP sector in China. To help better understand the business implications of these changes, the Berkeley Center for Law and Technology is planning on hosting a half-day roundtable discussion on pharmaceutical IP developments in China on May 30, one day before the comment period closes. Seats are limited. Please contact email@example.com or firstname.lastname@example.org for further information.